NervGen Pharma

Historical price data

NervGen Pharma is pioneering a novel approach to treating nervous system damage by targeting the body's natural repair mechanisms. The company's core technology focuses on overcoming inhibitory signals in the damaged nervous system to enable regeneration and functional recovery. Its lead asset, NVG-291, is advancing through clinical trials with promising early data, positioning NervGen as a key player in the neuroregeneration field. The company's strategy targets multiple high-need neurological conditions with significant unmet medical need.

Proprietary platform targeting the protein tyrosine phosphatase sigma (PTPσ) receptor to overcome inhibitory signals and promote nervous system repair and functional recovery following injury or in neurodegenerative disease.

2 drugs in pipeline

Total raised: $15M

NervGen faces competition from other companies pursuing neural repair, such as ReNetX Bio and BioAxone, but its specific PTPσ target is unique. Differentiation lies in its systemic administration and potential to treat diffuse neural damage. The primary competitive threat long-term is from large pharma with greater resources, should they enter the regenerative space.